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Abstract
Regulatory T cells (Treg) are important for immune homeostasis and are considered of
great interest for immunotherapy. The paucity of Treg numbers requires the need for ex vivo
expansion. Although therapeutic Treg flow-sorting is feasible, most centers aiming at Treg-
based therapy focus on magnetic bead isolation of CD4+CD25+ Treg using a good
manufacturing practice compliant closed system that achieves lower levels of cell purity.
Polyclonal Treg expansion protocols commonly use anti-CD3 plus anti-CD28 monoclonal
antibody (mAb) stimulation in the presence of rhIL-2, with or without rapamycin. However,
the resultant Treg population is often heterogeneous and pro-inflammatory cytokines like
IFNγ and IL-17A can be produced. Hence, it is crucial to search for expansion protocols that
not only maximize ex vivo Treg proliferative rates, but also maintain Treg stability and pre-
serve their suppressive function. Here, we show that ex vivo expansion of low purity mag-
netic bead isolated Treg in the presence of a TNFR2 agonist mAb (TNFR2-agonist)
together with rapamycin, results in a homogenous stable suppressive Treg population that
expresses FOXP3 and Helios, shows low expression of CD127 and hypo-methylation of
the FOXP3 gene. These cells reveal a low IL-17A and IFNγ producing potential and hardly
express the chemokine receptors CCR6, CCR7 and CXCR3. Restimulation of cells in a pro-
inflammatory environment did not break the stability of this Treg population. In a preclinical
humanized mouse model, the TNFR2-agonist plus rapamycin expanded Treg suppressed
inflammation in vivo. Importantly, this Treg expansion protocol enables the use of less pure,
but more easily obtainable cell fractions, as similar outcomes were observed using either
FACS-sorted or MACS-isolated Treg. Therefore, this protocol is of great interest for the ex
vivo expansion of Treg for clinical immunotherapy.
Introduction
Following identification of Treg, the immunomodulating role of Treg was demonstrated in a
variety of preclinical autoimmunity and transplantation models. Their clinical relevance was
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highlighted by demonstrating that the immunosuppressive function of Treg was hampered in
autoimmunity and allergy. Clinical application of Treg has been hampered by the paucity of Treg
cell numbers and the fact that standard methods of ex vivo Treg expansion produce heteroge-
neous cell populations [1]. For clinical application of Treg-based immunotherapy isolation of
Treg using a good manufacturing practice (GMP) system is required. Clinical grade flow-sorting
which retrieves highly pure Treg is restricted to a few clinic centers worldwide. In contrast, mag-
netic bead isolation of CD4+CD25+ Treg using a GMP compliant closed system, such as Clini-
MACS, that results in lower Treg purity [2] is more generally used. For Treg expansion most
centers apply polyclonal expansion protocols making use of anti-CD3 plus anti-CD28mAb stim-
ulation in the presence of rhIL-2 together with or without rapamycin [2–8]. This results in a het-
erogeneous Treg population revealing inadvertent pro-inflammatory (IL-17A, IFNγ) cytokine
producing potential [9]. The fact that human Treg could lose FOXP3 expression and suppressive
functions and acquire the capacity to produce pro-inflammatory cytokines under pro-inflamma-
tory micro-environmental conditions [10, 11] might have important implication for Treg-based
clinical therapy. Therefore, it is essential to develop highly efficacious expansion protocols that
promote strong Treg proliferation whilst maintaining or promoting Treg stability and suppressor
function. We and others have evidence that pharmaceutical agents influence Treg phenotype and
functional capacity [12–14], indicating that by delicate selection of pharmaceutical agents it is
possible to further support the stability of human Treg. In this respect, the mTOR inhibition by
rapamycin is an interesting example, since it has been shown to promote preferential outgrowth
of highly suppressive Treg [4, 14, 15]. In contrast to effector T cells (Teff), Treg are less sensitive
to mTOR inhibition by rapamycin since Treg proliferation and survival preferentially depends
more on the STAT5 [16] and Pim kinase pathways [17].
Tumour necrosis factor receptor 2 (TNFR2) expression, in contrast to TNFR1, is restricted
to lymphocytes and mainly binds membrane bound TNF instead of soluble TNF [18]. The
binding of TNFα to TNFR2 provides costimulatory signals to T cells that enhance T cell prolif-
eration and cell survival [19]. TNFR2 signalling is important for Treg, as TNFR2 deficient mice
had reduced numbers of thymic and peripheral Treg [20], and TNFR2 -/- Treg were not able to
control inflammatory responses in vivo [21]. Human Treg also express a higher level of TNFR2
than Teff [22, 23], and TNFR2+ Treg exhibited the most potent suppressive capacity [24]. The
interaction of TNF-TNFR2 promotes Treg proliferation and survival via the activation of the
NFκB pathway [25]. The fact that a TNFR2-agonist drives human Treg into a homogeneous
population with potent suppressive capacity [22] indicates that TNFR2 is a valuable target for
facilitating ex vivo expansion of human Treg. In this study, we show that expansion of low
purity MACS-isolated human Treg in the presence of TNFR2-agonist and rapamycin results in
a stable homogenous FOXP3+, Helios+, CD127low Treg population that shows profound sup-
pressor potential both in vitro, and in vivo in a preclinical humanized mouse model. Irrespec-
tive of the purity of Treg at the start of cell culture, i.e. either low purity MACS-isolated or high
purity FACS-sorted Treg, cells expanded in the presence of TNFR2-agonist plus rapamycin,
showed a stable Treg phenotype and potent suppressive capacity. Re-stimulation of cells in a
pro-inflammatory environment did not break the stability of this Treg population. Thus, a
TNFR2-agonist based expansion protocol shows great potential for ex vivo Treg expansion for
clinical purposes.
Materials and Methods
Isolation of Treg
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation
(Lymphoprep, Nycomed Pharma AS, Oslo, Norway) of buffy coats obtained from healthy
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blood donors (Sanquin Blood Bank, Region South-East, Netherlands) upon written informed
consent, according to the Dutch law. CD4+ T cells were enriched using the RosetteSepTM
human CD4+ T cell enrichment cocktail and processed according to manufacturer’s recom-
mendations (StemCell Technologies, Vancouver, Canada). This resulted in a>95% purified
CD4+ T cells and the absence of CD8+ cells. To obtain high purity Treg, FACS sorting of CD4
+CD25high Treg was performed using a BD FACSAria cell sorter (BD Biosciences, Erembode-
gem, Belgium) after labeling CD4+ cells with CD25/Pe-Cy7(M-A251; BD Biosciences), termed
as FACS-sorted Treg. More than 97% of Treg were FOXP3+ after cell sorting. Less pure
MACS-isolated CD4+CD25+ Treg were prepared using human CD25 microbeads (Miltenyi
Biotech, Bergisch Gladbach, Germany), according to manufacturer’s instructions. To mimic
the purity of clinic grade isolation, 15–20 μL of CD25 microbeads for every ten million CD4+
cells were used. The resultant Treg were 60–80% positive for FOXP3.
Flow cytometry
Cells were phenotypically analyzed using a multicolor flow cytometer Navios (Beckman-Coul-
ter, Mijdrecht, Netherlands). The following conjugated mAb were used: CD127(R34.34)/
APC-AF700, CD25(M-251)/APC or /Pe-Cy7 (BD), CD27(1A4-CD27)/PE-Cy5.5, CD3
(UCHT1)/ECD, CD4(1388.2)/PE-Cy5.5, CD62L(DREG56)/ECD, HLA-DR(Immun-357)/
FITC, CD8(B9.11)/APC-AF700, (all from Beckman-Coulter), CCR6(11A9)/Biotin (BD Biosci-
ence), CCR7(150503)/PE (R&D, Minneapolis, US), CXCR3(G025H7)/APC-Cy7 (Biolegend,
San Diego, US), TNFR2(MR2-1)/FITC (Hycult, Uden, Netherlands), TNFR2 (#22235) /APC
(R&D, Minneapolis, US), and Fix-viable-Dye labeled with APC-eFluo780 (eBioscience,
Vienna, Austria). For intracellular staining, FOXP3 (PCH101) /eFluo660 and Helios(22F6)/
AlexFluo647 (both from eBioscience) were used after fix-perm-treatment of cells, according to
the manufacturer’s instructions. For intracellular cytokine staining, cells were stimulated with
phorbolmyristate acetate (PMA, 12.5 ng/mL), ionomycin (500 ng/mL) and brefeldin A (5 μg/
mL) for 4 hours before starting of FACS staining. IFNγ(45.B3)/Pe-Cy7 and IL-17A (eBio64-
DEC1) /Alexa488, (both from BD Bioscience) were used. Isotype matched antibodies were
used to define marker settings. Data were analyzed using the software Kaluza (Beckman-
Coulter).
Protocols used for ex vivo Treg expansion
1. High purity FACS-sorted Treg (5 x 104) were stimulated with anti-CD3/anti-CD28 mAb-
coated microbeads (Cat. no. 11131D, Invitrogen, Bleiswijk, Netherlands) in a 1:2 bead-to-
cell ratio and exogenous rhIL-2 (200 U/mL, Proleukine, Amsterdam, Netherlands).
TNFR2-agonist (2.5 μg/mL, mAb MR2-1, Hycult) and/or rapamycin (1μM, Sigma-Aldrich,
Zwijndrecht, Netherlands) was added at the start of the cultures. Cells were harvested and
analyzed at day 7 as described.
2. Low purity MACS-isolated Treg (5 x 104) were stimulated with anti-CD3/anti-CD28 mAb-
coated microbeads (Cat. no. 11131D, Invitrogen) in a 1:2 bead-to-cell ratio. TNFR2-agonist
(2.5 μg/mL, Hycult) and/or rapamycin (1μM) was added at the start of the cultures. On day
2, exogenous rhIL-2 (750 U/mL) was added to the culture. Every 2 or 3 days the culture
medium was replenished by fresh culture medium containing rapamycin (1μM) (until day
7) and 750 U/mL rhIL-2. On day 9, additional TNFR2-agonist (2.5 μg/mL) was supple-
mented. On day 16, cells were harvested and analyzed.
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Co-culture suppression assays
The suppressor capacity of expanded Treg was studied using co-culture suppression assays.
Treg were expanded for 7 (FACS-sorted Treg) or 16 (MACS-isolated Treg) days under the con-
ditions described. Thereafter, Treg were collected, washed and added at different ratio’s to
CFSE-labeled CD4+CD25- responder T cells (Tresp) together with anti-CD3/anti-CD28 mAb-
coated beads (1:5 bead-to-cell ratio) for 3 days. Proliferation of Tresp was determined by ana-
lyzing CFSE dilution as described previously [26].
FOXP3 gene methylation
The FOXP3methylation status was analyzed by bisulphate sequencing as described previously
[27]. In brief, geneGenomic DNA was isolated from either MACS-isolated CD4+CD25+ Treg
or expanded Treg under each treatment group using the QIAamp DNABloodMini kit (Qiagen,
Venlo, Netherlands), Bisulfite converted and amplified using bisulfite-specific polymerase
chain reaction (PCR) (forward 59 TGGATATTTGGTTAGAGT TAAGAAT 39 and reverse 59
ACCTAACACTCTCAAAACTTCAAAC 39). The purified PCR product was sequenced on an
ABI 3130 Genetic Analyzer (Applied Biosystems, Bleiswijk, Netherlands), and analyzed using
Sequencing Analysis version 5.4 software (Applied Biosystems).
Humanized skin inflammation mouse model
The humanized skin inflammation mouse model used in this study has been described previ-
ously [28]. In brief, human abdominal skin from healthy individuals obtained after elective sur-
gery (Sannavisie Bodyclinic, Mill, Netherlands) was transplanted onto 6–8 week old female
B17.B6-PrkdcscidLystbg/Crl (SCID/beige) mice, and allowed to engraft for 3 weeks. Next, mice
were intra peritoneally (i.p) injected with 10–40 x 106 huPBMC in the absence or presence
of rapamycin expanded Treg (RapTreg) or Rapamycin plus TNFR2-agonist expanded Treg
(R/TTreg) at a ratio huPBMC: Treg of 1:1 or 1:2. Mice were sacrificed 3 weeks after the injection
of the human immune cells. Tissues of interest were collected, and the histological analysis of
the grafts was performed thereafter.
All the animal experimental procedures were in accordance with the international welfare
guidelines taking into consideration of the 3Rs (Refinement, Reduction, and Replacement) and
approved by the institutional ethical animal care committee of the Radboud University Nijme-
gen (Number DEC2013-023). Mice were sacrificed using the orbita extraction under anesthesia
followed by cervical dislocation. The use of human skin and peripheral blood were approved
and in accordance with the regulations set by the Medical Ethical Committees for human
research of the Radboudumc. Human skin (from elective surgery) and buffy coats were from
healthy donors, who gave written informed consent for scientific use. Buffy coats were pur-
chased from Sanquin Blood Bank, Nijmegen, Netherlands.
Histology & Immunohistochemistry
Human skin grafts were fixed in neutral buffered 4% formalin (Mallinckrodt Baker, Inc Deven-
ter, Netherlands) for 4 hours, processed and embedded in paraffin. Then, 6 μm sections were
cut and the slides were stained with Hematoxylin-Eosin (HE) or processed for immunohisto-
chemical staining. Human CD3 mAb (clone7.2.38, Abcam, Cambridge, UK) was used to stain
human CD3+ T cells. Antibody stainings were visualized using the Dako Cytomation EnVi-
sion+system-HRP (ABC) kit (DAKO, Glostrup, Copenhagen, Denmark) combined with 3,3’-
diaminobenzidine tetrahydrochloride (DAB, brown, Sigma-Aldrich). Sections were
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photographed using a microscope (Axiokop2 MOT; Zeiss, Sliedrecht, Netherlands), digital
camera (Axiocam MRc5; Zeiss) and AxioVision software (Zeiss).
Determination of epidermal thickness
Histologic assessment of the grafts was performed using the light microscopy after transplanta-
tion of human skin. The mean epidermal thickness was calculated using the program Visio-
pharm Integrator System (VIS) (Visiopharm, Hørsholm, Denmark) as epidermal area divided
by epidermal surface length.
Image analysis of immunohistochemistry
To enumerate human CD3+ T cells, representative pictures were made at 20× magnification. A
representative region of interest (ROI) was drawn from the lowest epidermal papilla till 300
mm depth into the dermis. Cell quantification was performed by setting a threshold and relat-
ing this to a number of cells per mm2. For evaluation of number of CD3+ cells, positively
stained cells were counted manually in CD3 infiltrated areas of the tissues and the number was
reported per mm2.
Statistics
Statistical analysis was performed using the GraphPad Prism software version 5.0 (GraphPAd
Software Inc., San Diego, US). For comparison between two groups, a Wilcoxon paired t-Test
was used. For comparison among multiple groups, a Kruskal-Wallis test plus Dunns post hoc
test or Friedman test plus Dunns post hoc test was used, where appropriate. P values of<0.05
were considered significant.
Results
Expansion of high purity FACS-sorted Treg in the presence of
TNFR2-agonist and rapamycin preserves Treg suppressor function and
stability
We began by examining the expression of TNFR2 on human CD4+ T cells. Based on the
expression of CD25 and FOXP3, CD4+ T cells were gated as CD25highFOXP3+, CD25int-
FOXP3-, and CD25negFOXP3- subsets. The CD25highFOXP3+ subset showed the highest
expression levels of TNFR2. High expression of TNFR2 on Treg was further confirmed by
showing that in contrast to the high numbers of positive cells in the CD25+FOXP3+ popula-
tion, only few CD25+FOXP3- cells expressed this receptor (Fig 1A). Next, we studied the effect
of additional TNFR2-agonist [22] stimulation on suppressor function and stability of highly
purified Treg. To this end, high purity FACS-sorted human CD4+CD25high Treg were stimu-
lated using anti-CD3/CD28-mAb coated beads and rhIL-2, in the presence or absence of
TNFR2-agonist and/or rapamycin, and cultured for a week (Fig 1B). Purity of the Treg popula-
tion based on FOXP3 expression was 93.5% ± 3 (Mean ± SD), and 80.1% ± 2.5 (Mean ± SD) of
these cells co-expressed Helios, which is in line with the literature [29] that states that Helios+-
and Helios- subsets co-exist within human FOXP3+ Treg. Upon stimulation with CD3/CD28
mAb-coated microbeads in the presence of 200U/ml recombinant human IL-2, a percentage of
Treg lost the expression of FOXP3, whereas the presence of rapamycin-only or TNFR2-agonist
plus rapamycin helped Treg maintain FOXP3 and enhanced Helios expression. Interestingly,
the expression of HLA-DR, a molecule associated with potent Treg suppressive function [30],
was highly enhanced by the use of TNFR2-agonist (Fig 1C). With regard to chemokine recep-
tor expression, CCR5 was hardly expressed on Treg, regardless of the condition tested.
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Combined use of TNFR2-agonist plus rapamycin down-regulated CCR6 and CXCR3 expres-
sion, but hardly affected CCR7 as compared to CD3/CD28 stimulation in the presence or
absence of rapamycin (S1 Fig),
An important feature of Treg is their suppressive capacity. We assessed this functional
capacity in a CFSE-based co-culture suppression assay, using autologous CD4+CD25- T cells
as responder cells. Treg expanded with TNFR2-agonist plus rapamycin (R/TTreg) showed
enhanced suppressor capacity as compared to Treg expanded in the absence (CtrlTreg) or pres-
ence of rapamycin-only (RapTreg) (Fig 2A).
Previously, others and we described that Treg can lose their stability and start to produce
pro-inflammatory cytokines [10, 11]. To analyze the stability of Treg that were expanded in the
presence of TNFR2-agonist plus rapamycin, we analyzed their IL-17A and IFNγ producing
potential. Under the given stimulatory conditions Treg expanded in the presence of Rap, or
Rap+TNFR2 agonist revealed very low levels of IL-17A or IFNγ (Fig 2B).
TNFR2-agonist promotes efficient ex vivo expansion of lower purity
MACS-isolated Treg into a highly stable homogenous Treg population
Then, we further explored the effect of stimulation with the TNFR2-agonist using MACS-iso-
lated, and thus less pure but more easily obtainable, CD4+CD25+ human Treg. We employed
a well established Treg expansion protocol [22] that includes anti-CD3/CD28 mAb coated
microbead stimulation, high dose rhIL-2 and rapamycin (Fig 3A). To mimic the moderately
pure Treg isolated using CliniMACS1 which is typically around 40–60% of CD4+CD25high
cells [2], we prepared human Treg by using laboratory based MiniMACS1 with a modified
amount of CD25 beads, thus resulting in a lower purity of Treg as analyzed by the expression
of FOXP3 (65.6% ± 18, mean ± SD, Fig 3B). Interestingly, the fold expansion of MACS-isolated
Treg in the combined use of TNFR2-agonist plus rapamycin was significantly increased (mean
23-fold expansion) as compared to that of rapamycin-only (mean 12-fold expansion) (Fig 3C).
This data indicate that combined use of TNFR2-agonist plus rapamycin could overcome the
rapamycin-mediated inhibition of Treg proliferation. Due to the usage of a high amount of
rhIL-2 in the expansion protocol, which has shown its critical role in the lineage maintenance
of both murine and human Treg [31, 32], FOXP3 expression in the CD3/CD28 group was
largely preserved upon stimulation. Interestingly, expression levels of Helios (MFI) and
HLA-DR (percentage and MFI) on R/TTreg after expansion were significantly higher than
those on RapTreg; Under both conditions the expression of FOXP3 was preserved up to a simi-
lar level (Fig 3D).
Regarding the suppressor capacity of R/TTreg: these were superior to RapTreg, as at a lower
Treg:Tresp ratio (1:8), only R/TTreg, but not RapTreg, could significantly inhibit the
Fig 1. TNFR2-agonist preserves the expression of FOXP3 and enhances Helios and HLA-DR,
markers associated with highly suppressive function. (A) Flow cytometry analysis of human CD4+
cells immediately after cell preparation. Left panel: Histograms show the expression of TNFR2 within
CD25highFOXP3+, CD25intFOXP3-, and CD25negFOXP3- subsets. A representative experiment out of five is
shown. Numbers of %TNFR2+ cells (top) and mean fluorescence intensity of TNFR2 (low) are listed in the
histograms. Middle panel: Cumulative data showing the percentage of TNFR2+ cells within different cell
subsets as shown on the X-axis (N = 5). Right panel: Example overlay histogram showing the expression of
TNFR2 within CD25+FOXP3+ and CD25+FOXP3- subsets. A Friedman with Dunns post hoc test was used
for comparison among groups. Asterisks indicate significant differences. (B) Schematic overview of
expansion strategy for FACS-sorted Treg, as described in Materials and Methods. (C) Flow cytometry of high
purity FACS-sorted Treg before (input) and after cell expansion under the indicated conditions. Dot plots
showing surface expression of HLA-DR, and intracellular expression of FOXP3 and Helios. Numbers within
the gated regions show the percentage of positive cells. Data derived from two different healthy donors are
shown. Rap: rapamycin; Agonist: TNFR2-agonist.
doi:10.1371/journal.pone.0156311.g001
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proliferation of responder cells (Fig 4A). In addition, the TNFR2-agonist plus rapamycin
expanded Treg hardly showed the potential to produce IL-17A and IFNγ (Fig 4B), indicating
that R/TTreg are more stable than RapTreg. Expansion of low purity MACS-isolated Treg in the
presence of TNFR2-agonist plus rapamycin resulted in a homogenous Treg population that
expressed CD62L, CCR7, and CD27, lacked expression of CCR5 and CCR6, while a limited
percentage of cells expressed CXCR3 (Fig 4C). This homogenous Treg phenotype and the high
suppressive capacity were comparable to the results obtained with high purity FACS-sorted
Treg, suggesting that this protocol is of interest for clinical grade ex vivo expansion of low
purity, but easily obtainable Treg.
As Treg stability and suppressor function critically depends on the stable expression of
FOXP3, which in turn depends on hypo-methylation of a CpG rich region in the FOXP3 gene,
called the TSDR, we hypothesized that stimulation by TNFR2-agonist plus rapamycin of Treg
promotes demethylation of the TSDR. To test this, low purity MACS-isolated Treg were
expanded according to the protocol mentioned and the TSDR demethylation status was ana-
lyzed using bi-sulphite sequencing. The significant increase of TSDR demethylation was only
observed in TNFR2-agonist plus rapamycin expanded cells, but not in case of rapamycin or
TNFR2-agonist only group (Fig 4D). This TNFR2-agonist plus rapamycin induced hypo-
methylation of the FOXP3 gene likely explains the increased suppressor capacity and high sta-
bility of Treg population expanded under these conditions.
Previously, we showed that stimulation of human Treg in a pro-inflammatory environment
enhances the IL-17A producing potential of Treg [10]. Having established that Treg expansion
in the presence of TNFR2-agonist plus rapamycin results in increased stability of the Treg pop-
ulation, we questioned whether re-stimulation of these cells in a pro-inflammatory environ-
ment could break the stability and promote the IL-17A producing potential. To examine this,
low purity MACS-isolated Treg were expanded according to the protocols mentioned, and the
resultant Treg were subsequently re-stimulated with anti-CD3/CD28 beads and rhIL-2 in the
absence or presence of the pro-inflammatory cytokines IL-1β or IL-23. Re-stimulation of these
expanded Treg in the presence of IL-1β or IL-23 neither led to the loss of FOXP3 expression,
nor the increase in IL-17A producing potential (Fig 4E), further stressing the stability of these
expanded Treg.
In conclusion, 16 days expansion of low purity MACS-isolated Treg in the presence of
TNFR2-agonist and rapamycin results in a highly pure, homogenous and very stable Treg
population.
TNFR2-agonist plus rapamycin expanded Treg inhibit inflammation in a
humanised mouse model
Next, using a pre-clinical humanised skin inflammation mouse model, we sought to establish
whether TNFR2-agonist plus rapamycin expanded low purity MACS-isolated Treg could sup-
press inflammation in vivo. To this end, SCID mice were transplanted with a human skin graft,
whereupon 21 days after engraftment of the human skin, PBS (as a control) or allogeneic
Fig 2. TNFR2-agonist plus rapamycin expanded FACS-sorted Treg reveal a high suppressive capacity and less IL-17A and IFNγ producing
potential.High purity FACS-sorted human Treg were stimulated as described in Material and Methods. At day 7 of the cell cultures, expanded Treg
were harvested, washed, and analyzed for their suppressive capacity in a CFSE-based co-culture suppression assay. CtrlTreg, RapTreg and R/TTreg
represent cells expanded in the absence or presence of rapamycin-only or TNFR2-agonist plus rapamycin, respectively. (A) Histograms showing the
inhibition of proliferation of responder cells following the addition of graded doses of Treg. The ratio of Treg:Tconv is indicated on the top. Numbers
show the percentage of divided cells. (B) Flow cytometry of intracellular IL-17A and IFNγ of Treg before (day 0) and after expansion under the
indicated conditions. Data derived from two different healthy donors are shown. Numbers show the percentage of positive cells. Rap: rapamycin;
Agonist: TNFR2-agonist.
doi:10.1371/journal.pone.0156311.g002
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human PBMC (huPBMC) were injected intra peritoneally. Typically, the latter results in a
strong inflammatory response of the human skin 3 weeks after infusion, which is characterized
Fig 3. TNFR2-agonist facilitates ex vivo expansion of low purity MACS-isolated human Treg. (A) Schematic overview of low purity
MACS-isolated Treg expansion strategy as described in Materials and Methods. (B) Dot plots showing a representative FOXP3 expression
pattern after MACS isolation of Treg, as shown in the cumulative data graph (N = 10, right panel). (C) Cumulative graph showing fold
expansion of low purity Treg that were stimulated under the conditions as indicated on the X-axis (N = 5). A Friedman test was used for
comparison of three groups. (D) Flow cytometry of surface expression of HLA-DR, and intracellular expression of FOXP3 and Helios of
MACS-isolated Treg before (input) and after expansion under the indicated conditions. Numbers within the quadrant gates show the
percentage of positive cells. Cumulative data of %FOXP3+Helios+, %FOXP3+HLA-DR+, the median fluorescence intensity (MFI) of Helios
and HLA-DR are shown in the right panel, respectively. Wilcoxon paired t-Test and Kruskal-Wallis test were used for comparison between
two and multiple groups, respectively. Asterisks indicate significant differences. Rap: rapamycin; Agonist: TNFR2-agonist.
doi:10.1371/journal.pone.0156311.g003
Stable Human Treg Expansion via the Receptor TNFR2
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Fig 4. TNFR2-agonist preserves the stability of low purity MACS-isolated Treg during ex vivo expansion. Low
purity MACS-isolated human Treg were cultured as described under Materials and Methods. Thereafter, the
expanded Treg were harvested, washed, and analyzed for their suppressor capacity in a CFSE-based co-culture
Stable Human Treg Expansion via the Receptor TNFR2
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by thickening of the epidermis and influx of human lymphocytes [28]. Systemic repopulation
of human lymphocytes was observed as indicated by the increased size of mouse spleen (Fig
5B). Both TNFR2-agonist plus rapamycin expanded Treg and rapamycin-only expanded Treg
were suppressive, as indicated by a reduction of epidermal thickening (Fig 5C) and human T
cell numbers in the dermis of the grafted skin (Fig 5D); under the given conditions levels of in
vivo inhibition were not significantly different between the two types of Treg.
Discussion
An important issue for Treg-based immunotherapy is to maintain stability and suppressive
function of Treg during and after ex vivo expansion and following their transfer into patients.
Although clinical grade high purity Treg isolation by GMP flow cytometry is available in a few
medical centres worldwide, most clinic centres use GMP qualified magnetic bead based isola-
tion techniques that result in limited Treg purity. Hence, in this study we focused on optimiz-
ing an ex vivo Treg expansion protocol that produces high numbers of stable potent human
Treg starting with low purity magnetic bead isolated Treg. We found that the combined use of
TNFR2-agonist and rapamycin promotes Treg proliferation rates, enhances TSDR demethyla-
tion and increases both Treg stability and function in vitro. Low purity Treg expanded in the
presence of TNFR2-agonist plus rapamycin suppressed in vivo inflammation in a humanized
mouse model.
TNFα has both pro-inflammatory and anti-inflammatory effects. It binds to two structur-
ally related but functionally distinct receptors TNFR1 and TNFR2. In general, TNFR1 is
responsible for TNFα-mediated cell apoptosis, and TNFR2 for any function related to T cell
survival. In contrast to the ubiquitous expression of TNFR1, TNFR2 expression is more limited
to myeloid and lymphoid cell lineages [18]. Interestingly, human Treg, as opposed to CD25-
Tconv cells, constitutively express high levels of TNFR2, and TNFR2+ Treg reveal the most
potent suppressive capacity [20, 24]. The effect of TNFα on Treg suppressor function remains
controversial. Some groups reported that TNFα/TNFR2 signalling inhibits human Treg sup-
pressive function [33, 34], other groups found that TNFα increases FOXP3 expression and sup-
pressive activity, and that TNFR2 is crucial for sustaining FOXP3 expression and maintaining
the stability of murine Treg in an inflammatory environment [20]. It should be noted that a
more recent study revealed that the nature of the TNFR2 antibodies used in these studies was
likely different (agonistic versus antagonistic) [22]. In this study, we found that stimulation of
human Treg with a TNFR2-agonist antibody preserved a stable Treg phenotype and function
after ex vivo expansion. It is known that TNFα induces a TNFR2/NFκB dependent pathway in
suppression assay. CtrlTreg, RapTreg and R/TTreg represent cells expanded in the absence or presence of
rapamycin-only or TNFR2-agonist plus rapamycin, respectively. (A) Histograms showing the inhibition of
proliferation of Tresp following the addition of graded doses of Treg. The ratios of Treg:Tresp are indicated on the
top. Numbers in the histograms show the percentage of divided cells. Cumulative data (N = 6) are shown in the right
panel. (B) Flow cytometry of intracellular IL-17A and IFNγ of Treg at the start of the culture (day 0) and after
expansion under the indicated conditions. Dot plots showing representative data of N = 4–7 individuals as shown in
the cumulative data graph (right panel). Numbers show the percentage of positive cells. Each line represents Treg
derived from a specific donor were expanded under the conditions described on the X-axis. (C) Expression of
CXCR3, CCR5, CCR6, CCR7, CD62L and CD27 before (day 0) and after expansion (day 16). Numbers show the
percentage of positive cells. (D) Bisulphite sequencing of the TSDR of expanded Treg. Each dot represents a single
experiment. (E) Expanded Treg were harvested, rested overnight, and then restimulated with anti-CD3/anti-CD28
beads in a 1:2 ratio of beads to cells, in the absence or presence of IL-1β (50 ng/mL) and IL-23 (50 ng/mL) for
2-days. Exogenous rhIL-2 (200 U/mL) was included in the cell cultures. Thereafter, intracellular production of IL-17A
was analyzed using flow cytometry. Cumulative data derived from seven different donors are shown. A Friedman
plus Dunns post hoc test (A, D, and E) or Kruskal-Wallis plus Dunns post hoc test (B) were used for comparison
among multiple groups. Asterisks indicate significant differences. Rap: rapamycin; Agonist: TNFR2-agonist.
doi:10.1371/journal.pone.0156311.g004
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human Treg, and that an increase in NFκB activity promotes FOXP3 expression [33]. Using
TNFR2-agonist only was enough to prevent the loss of FOXP3 expression during ex vivo
expansion, whereas sustained hypo-methylation of TSDR required both rapamycin and
TNFR2-agonist, suggesting that stabilization of FOXP3 expression requires both mTOR and
NFκB signal pathways. One of the major concerns in Treg therapy is the plasticity of Treg, and
the hypomethylation of TSDR is well correlated to the loss of Treg stability [35]. In vitro re-
Fig 5. TNFR2-agonist plus rapamycin expanded Treg inhibit inflammation in a humanised mouse
model. (A) Schematic overview of the humanised skin inflammation mouse model used. In brief, SCID mice
were transplanted with a human skin graft, 21 days after engraftment, PBS (as a control), or allogeneic human
PBMC (huPBMC) only or huPBMC plus Treg of interest (at a ratio of 1:1) were injected intra peritoneally. 26
days later the animals were sacrificed to analyze the mouse spleen and human skin grafts. RapTreg and R/
TTreg refer to low purity MACS-isolated Treg expanded for 16-days in the presence of rapamycin-only or
TNFR2-agonist plus rapamycin, respectively. (B) Representative photographs of spleens derived frommice
infused with PBS, huPBMC only, or huPBMC plus Treg of interest, 21 days after the skin transplantation.
Cumulative data showing the weight of spleens derived from N = 4 mice (right panel; n.d. = not determined).
(C) Representative photographs showing histology (HE staining) of human skin grafts. Left panel: 10 x
magnification. Right panel shows the epidermal thickness (μm) of human skin grafts following infusion of PBS,
huPBMC, huPBMC plus RapTreg or huPBMC plus R/TTreg. Mean ± SD, N = 6. (D) Immunohistochemistry of
human CD3+ (brown) T cell infiltration in the human dermis. A representative photograph of N = 4 as
presented in the cumulative data graph is shown (right panel; Mean ± SD). 20 x magnification. Wilcoxon paried
t Test was used to compare the group of mice infused with huPBMC only with other groups of mice infused with
huPBMC plus Treg of interest. Asterisks indicate significant differences.
doi:10.1371/journal.pone.0156311.g005
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stimulation of TNFR2-agonist plus rapamycin expanded Treg led to neither the loss of FOXP3
expression, nor the enhancement of IL-17A production, especially under pro-inflammatory
conditions, suggesting a well preserved Treg stability. This observation appears to be supported
by our in vivo data acquired from a humanized mouse model for skin inflammation.
The clinical application of Treg based adoptive therapy in transplantation and autoimmu-
nity is hampered by the paucity of peripheral Treg numbers, purity of clinical grade isolated
Treg and stability and function of ex vivo expanded Treg. Current protocols used for Treg ex
vivo expansion commonly use anti-CD3 and anti-CD28 mAb stimulation in the presence of
rhIL-2 [2–8]. This treatment alone typically results in a heterogeneous Treg population reveal-
ing inadvertent pro-inflammatory (like IL-17A, IFNγ) cytokine producing potential [9–11].
Moreover, Treg isolation using the GMP CliniMACS1 system leads to a moderately pure
Treg population, with around 40–60% CD4+CD25high cells [2]. Considering the intrinsic
reduced ability of Treg to proliferate in vitro, “contaminating” non-Treg cells might overgrow
Treg during ex vivo expansion. One solution is to include rapamycin, an effective inhibitor of
effector T cells, in the expansion culture. However, addition of rapamycin generally leads to
lower overall cell yields [36]. Consistent with the report that TNFR2/NFκB pathways stimulate
human Treg proliferation [33], combined use of TNFR2-agonist and rapamycin resulted in
efficient Treg proliferation. These fully expanded Treg were even more suppressive than cells
expanded in the presence of rapamycin-only. Previous studies showed that the use of rapamy-
cin leads to the inhibition of IL-17A and IFNγ production [37]. Intriguingly, combined use of
TNFR2-agonist and rapamycin further prevented IL-17A and IFNγ production, as compared
to rapamycin-only treatment. Moreover, the percentage of CCR6 positive cells, a marker that
identifies IL-17-producing cells derived from human Treg [10], was also low following the
treatment with TNFR2-agonist plus rapamycin. A recent study showed that TNFR2 knock out
CD4+ T cells had increased expression of RORγt and IL-17 production, which was dependent
on the impairment of TNFR2-mediated activation of NFκB [38]. We speculate that a similar
process of regulation may exist in human Treg where TNFR2/NFκB signalling might act as a
double-edged sword to enhance FOXP3, but inhibit RORγt expression, thus contributing to
the stabilization of Treg.
Previous studies indicated that TNFR2 is more densely expressed on human CD45RA-acti-
vated Treg [33]. Therefore, stimulation with a TNFR2-agonist might mainly induce the prolif-
eration of a memory Treg subset. Indeed, one of the most notable surface markers that was up-
regulated by stimulation in the presence of TNFR2-agonist was HLA-DR, which identifies an
effector Treg subset that exhibits higher FOXP3 expression and more potent suppression [30].
HLA-DR positive effector Treg were reported to be more sensitive to apoptosis than HLA-DR
negative Treg [39]. However, in this study, re-stimulation of R/TTreg, which expressed a high
level of HLA-DR, had a similar cell viability as CtrlTreg that express little HLA-DR. Analysis of
chemokine receptors expression showed that stimulation of the TNFR2-agonist led to reduced
expression of the chemokine receptors CXCR3 and CCR6, which are linked to Th1 and Th17
like cells, respectively. An implication of the lack of CXCR3 and CCR6 on the expanded Treg
might suggest that these cells upon infusion fail to migrate to sites of Th1 and Th17 responses.
However, all TNFR2-agonist expanded Treg showed CD62L expression, which might favour
their trafficking to secondary lymphoid organs, where they might further expand and receive
instruction with regard to tissue homing capacity [27].
In conclusion, we demonstrate the potential of additional TNFR2-agonist stimulation for ex
vivo expansion of low purity Treg. Expansion of low purity MACS-isolated human Treg in the
presence of TNFR2-agonist and rapamycin results in a stable homogenous FOXP3+Helios
+ Treg population that reveals potent suppressor potential both in vitro and in vivo, in a pre-
clinical humanized mouse model. Our findings further emphasize that expansion of bead-
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isolated Treg requires rapamycin for achieving a functional and stable Treg cell product. But,
the selection of an additional agent like TNFR2-agonist can overcome the rapamycin-mediated
inhibition of Treg proliferation, and even further stabilize the Treg phenotype based on the
demethylation status of TSDR region. It is thus of great interest to consider the combined use
of TNFR2-agonist and rapamycin for stable ex vivo Treg expansion for clinical application.
Supporting Information
S1 Fig. TNFR2-agonist down regulates the expression of CCR6 and CXCR3, while hardly
affecting CCR7 expression. Flow cytometry of FACS-sorted Treg after cell expansion under
the indicated conditions. Dot plots showing surface expression of CXCR3, CCR5, CCR6,
CCR7, CD62L and CD27 at day 7 of the cell cultures. Numbers within the quadrant gates show
the percentages of positive cells. Data derived from two different donors are shown. Rap: rapa-
mycin; Agonist: TNFR2-agonist.
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